» Articles » PMID: 38672792

Bone Disease in HIV: Need for Early Diagnosis and Prevention

Overview
Journal Life (Basel)
Specialty Biology
Date 2024 Apr 27
PMID 38672792
Authors
Affiliations
Soon will be listed here.
Abstract

The transformation of HIV into a manageable chronic condition has unveiled new clinical challenges associated with aging-related pathologies, including bone disease. This review explores the intricate relationship between HIV, antiretroviral therapy (ART), and bone disease, highlighting the necessity of early diagnosis and preventative strategies to mitigate the increased risk of osteopenia, osteoporosis, and fractures in people living with HIV (PLWHIV). It synthesizes the current literature to elucidate the multifactorial etiology of bone pathology in this population, that includes direct viral effects, chronic immune activation, ART-associated risks, and the impact of traditional risk factors for bone loss. Through a critical examination of modern diagnostic methods, lifestyle modifications, evidence-based preventive actions, and pharmacological treatments, the necessity for comprehensive management is highlighted, along with recommendations for integrated healthcare approaches vital for achieving optimal patient outcomes. By advocating for a proactive, patient-centered, and multidisciplinary strategy, this review proposes a plan to integrate bone health into standard HIV care through active risk identification, vigilant screening, effective preventive measures, tailored treatments, and informed decision-making, in an effort to ultimately enhance the quality of life for PLWHIV.

Citing Articles

Bone Loss and Fractures in Post-Menopausal Women Living with HIV: A Narrative Review.

Jamshaid M, Heidari A, Hassan A, Mital D, Pearce O, Panourgia M Pathogens. 2024; 13(9).

PMID: 39339002 PMC: 11435029. DOI: 10.3390/pathogens13090811.


Bone Tissue Changes in Individuals Living with HIV/AIDS: The Importance of a Hierarchical Approach in Investigating Bone Fragility.

Jadzic J, Dragovic G, Lukic R, Obradovic B, Djuric M J Pers Med. 2024; 14(8).

PMID: 39201983 PMC: 11355540. DOI: 10.3390/jpm14080791.

References
1.
Hoy J, Richardson R, Ebeling P, Rojas J, Pocock N, Kerr S . Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV. AIDS. 2018; 32(14):1967-1975. DOI: 10.1097/QAD.0000000000001911. View

2.
Mills A, Arribas J, Andrade-Villanueva J, DiPerri G, van Lunzen J, Koenig E . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2015; 16(1):43-52. DOI: 10.1016/S1473-3099(15)00348-5. View

3.
Delpino M, Quarleri J . Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis. Front Endocrinol (Lausanne). 2020; 11:502. PMC: 7493215. DOI: 10.3389/fendo.2020.00502. View

4.
Godos J, Giampieri F, Chisari E, Micek A, Paladino N, Forbes-Hernandez T . Alcohol Consumption, Bone Mineral Density, and Risk of Osteoporotic Fractures: A Dose-Response Meta-Analysis. Int J Environ Res Public Health. 2022; 19(3). PMC: 8835521. DOI: 10.3390/ijerph19031515. View

5.
Biver E . Osteoporosis and HIV Infection. Calcif Tissue Int. 2022; 110(5):624-640. PMC: 9013331. DOI: 10.1007/s00223-022-00946-4. View